These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33931772)

  • 1. A promising new therapy for ALS.
    Wood H
    Nat Rev Neurol; 2021 Jun; 17(6):327. PubMed ID: 33931772
    [No Abstract]   [Full Text] [Related]  

  • 2. GEMALS: A promising therapy for amyotrophic lateral sclerosis.
    Geffard M; Mangas A; Bedat D; Coveñas R
    Exp Ther Med; 2018 Apr; 15(4):3203-3210. PubMed ID: 29545836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing Stem Cell Therapy for Repair of Damaged Lung Microvasculature in Amyotrophic Lateral Sclerosis.
    Garbuzova-Davis S; Shell R; Mustafa H; Hailu S; Willing AE; Sanberg PR; Borlongan CV
    Cell Transplant; 2020; 29():963689720913494. PubMed ID: 32207340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cord blood as a potential therapeutic for amyotrophic lateral sclerosis.
    Garbuzova-Davis S; Ehrhart J; Sanberg PR
    Expert Opin Biol Ther; 2017 Jul; 17(7):837-851. PubMed ID: 28443372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Amyotrophic lateral sclerosis, a heterogeneous disorder].
    van Es MA; Kruitwagen-van Reenen ET; Schröder CD; Pasterkamp RJ; Veldink JH; van den Berg LH
    Ned Tijdschr Geneeskd; 2016; 160():A9658. PubMed ID: 26860749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling.
    Morello G; Conforti FL; Parenti R; D'Agata V; Cavallaro S
    Curr Med Chem; 2015; 22(17):2004-21. PubMed ID: 25850769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
    Abati E; Bresolin N; Comi G; Corti S
    Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
    [No Abstract]   [Full Text] [Related]  

  • 8. Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone.
    Distaso E; Milella G; Mezzapesa DM; Introna A; D'Errico E; Fraddosio A; Zoccolella S; Dicuonzo F; Simone IL
    J Neurol; 2021 Sep; 268(9):3307-3315. PubMed ID: 33655342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy.
    Bond L; Bernhardt K; Madria P; Sorrentino K; Scelsi H; Mitchell CS
    Front Neurosci; 2018; 12():10. PubMed ID: 29416499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rising Stars: Astrocytes as a Therapeutic Target for ALS Disease.
    Izrael M; Slutsky SG; Revel M
    Front Neurosci; 2020; 14():824. PubMed ID: 32848579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-ALS activity of alsin, the product of the ALS2 gene, and activity-dependent neurotrophic factor.
    Matsuoka M; Nishimoto I
    Neurodegener Dis; 2005; 2(3-4):135-8. PubMed ID: 16909018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice.
    Kim H; Kim HY; Choi MR; Hwang S; Nam KH; Kim HC; Han JS; Kim KS; Yoon HS; Kim SH
    Neurosci Lett; 2010 Jan; 468(3):190-4. PubMed ID: 19879334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis.
    Pollari E; Goldsteins G; Bart G; Koistinaho J; Giniatullin R
    Front Cell Neurosci; 2014; 8():131. PubMed ID: 24860432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational stem cell therapy for amyotrophic lateral sclerosis.
    Boulis NM; Federici T; Glass JD; Lunn JS; Sakowski SA; Feldman EL
    Nat Rev Neurol; 2011 Dec; 8(3):172-6. PubMed ID: 22158518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotrophic factors and amyotrophic lateral sclerosis.
    Ekestern E
    Neurodegener Dis; 2004; 1(2-3):88-100. PubMed ID: 16908980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.
    Yacila G; Sari Y
    Curr Med Chem; 2014; 21(31):3583-93. PubMed ID: 24934355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arimoclomol: a potential therapy under development for ALS.
    Lanka V; Wieland S; Barber J; Cudkowicz M
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1907-18. PubMed ID: 19938902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS.
    Petri S; Körner S; Kiaei M
    Neurol Res Int; 2012; 2012():878030. PubMed ID: 23050144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene, a promising estrogen replacement, limits TDP-25 cell death by enhancing autophagy and suppressing apoptosis.
    Zhou F; Dong H; Liu Y; Yan L; Sun C; Hao P; Liu Y; Zhai J; Liu Y
    Brain Res Bull; 2018 Jun; 140():281-290. PubMed ID: 29807145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of ALS and FTD: implications for translational studies.
    Liščić RM
    Arh Hig Rada Toksikol; 2015 Dec; 66(4):285-90. PubMed ID: 26751860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.